BACKGROUND: The prevalence and clinical course of pulmonary cryptococcosis in Sub-Saharan Africa are not well described. METHODS: Consecutive HIV-infected adults hospitalized at Mulago Hospital (Kampala, Uganda) between September 2007 and July 2008 with cough >or=2 weeks were enrolled. Patients with negative sputum smears for acid-fast bacilli were referred for bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid was examined for mycobacteria, Pneumocystis jirovecii, and fungi. Patients were followed 2 and 6 months after hospital discharge. RESULTS: Of 407 patients enrolled, 132 (32%) underwent bronchoscopy. Of 132 BAL fungal cultures, 15 (11%) grew Cryptococcus neoformans. None of the patients were suspected to have pulmonary cryptococcosis on admission. The median CD4 count among those with pulmonary cryptococcosis was 23 cells per microliter (interquartile range = 7-51). Of 13 patients who completed 6-month follow-up, 4 died and 9 were improved, including 5 who had started antiretroviral therapy but had not received antifungal medication. CONCLUSIONS: Pulmonary cryptococcosis is common in HIV-infected tuberculosis suspects in Uganda. Early initiation of antiretroviral therapy in those with isolated pulmonary infection may improve outcomes, even without antifungal therapy. This finding suggests that some HIV-infected patients with C. neoformans isolated from respiratory samples may have colonization or localized infection.
BACKGROUND: The prevalence and clinical course of pulmonary cryptococcosis in Sub-Saharan Africa are not well described. METHODS: Consecutive HIV-infected adults hospitalized at Mulago Hospital (Kampala, Uganda) between September 2007 and July 2008 with cough >or=2 weeks were enrolled. Patients with negative sputum smears for acid-fast bacilli were referred for bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid was examined for mycobacteria, Pneumocystis jirovecii, and fungi. Patients were followed 2 and 6 months after hospital discharge. RESULTS: Of 407 patients enrolled, 132 (32%) underwent bronchoscopy. Of 132 BAL fungal cultures, 15 (11%) grew Cryptococcus neoformans. None of the patients were suspected to have pulmonary cryptococcosis on admission. The median CD4 count among those with pulmonary cryptococcosis was 23 cells per microliter (interquartile range = 7-51). Of 13 patients who completed 6-month follow-up, 4 died and 9 were improved, including 5 who had started antiretroviral therapy but had not received antifungal medication. CONCLUSIONS:Pulmonary cryptococcosis is common in HIV-infected tuberculosis suspects in Uganda. Early initiation of antiretroviral therapy in those with isolated pulmonary infection may improve outcomes, even without antifungal therapy. This finding suggests that some HIV-infectedpatients with C. neoformans isolated from respiratory samples may have colonization or localized infection.
Authors: A D Grant; G Djomand; P Smets; A Kadio; M Coulibaly; A Kakou; C Maurice; J P Whitaker; F Sylla-Koko; D Bonard; S Z Wiktor; R J Hayes; K M De Cock; A E Greenberg Journal: AIDS Date: 1997-09 Impact factor: 4.177
Authors: Sarah E Kidd; Yat Chow; Sunny Mak; Paxton J Bach; Huiming Chen; Adrian O Hingston; James W Kronstad; Karen H Bartlett Journal: Appl Environ Microbiol Date: 2006-12-28 Impact factor: 4.792
Authors: M C Meyohas; P Roux; D Bollens; C Chouaid; W Rozenbaum; J L Meynard; J L Poirot; J Frottier; C Mayaud Journal: Clin Infect Dis Date: 1995-09 Impact factor: 9.079
Authors: W G Powderly; D Finkelstein; J Feinberg; P Frame; W He; C van der Horst; S L Koletar; M E Eyster; J Carey; H Waskin Journal: N Engl J Med Date: 1995-03-16 Impact factor: 91.245
Authors: C L Daley; F Mugusi; L L Chen; D M Schmidt; P M Small; E Bearer; E Aris; I M Mtoni; J P Cegielski; G Lallinger; I Mbaga; J F Murray Journal: Am J Respir Crit Care Med Date: 1996-07 Impact factor: 21.405
Authors: Alfred O Andama; Saskia den Boon; David Meya; Adithya Cattamanchi; William Worodria; J Lucian Davis; Nicholas D Walter; Samuel D Yoo; Nelson Kalema; Barbara Haller; Laurence Huang Journal: J Acquir Immune Defic Syndr Date: 2013-06-01 Impact factor: 3.731
Authors: Sofya Tokman; Christopher F Barnett; Leah G Jarlsberg; Pam R Taub; Saskia den Boon; J Lucian Davis; Adithya Cattamanchi; William Worodria; Alan Maisel; Laurence Huang Journal: Respirology Date: 2014-01-26 Impact factor: 6.424
Authors: Nicola K Wills; David S Lawrence; Elizabeth Botsile; Mark W Tenforde; Joseph N Jarvis Journal: Med Mycol Date: 2021-07-14 Impact factor: 4.076
Authors: Steve M Taylor; Steven R Meshnick; William Worodria; Alfred Andama; Adithya Cattamanchi; J Lucian Davis; Samuel D Yoo; Patrick Byanyima; Sylvia Kaswabuli; Carol D Goodman; Laurence Huang Journal: PLoS One Date: 2012-11-16 Impact factor: 3.240
Authors: David R Boulware; David B Meya; Tracy L Bergemann; Darin L Wiesner; Joshua Rhein; Abdu Musubire; Sarah J Lee; Andrew Kambugu; Edward N Janoff; Paul R Bohjanen Journal: PLoS Med Date: 2010-12-21 Impact factor: 11.069
Authors: J Lucian Davis; Laurence Huang; William Worodria; Henry Masur; Adithya Cattamanchi; Charles Huber; Cecily Miller; Patricia S Conville; Patrick Murray; Joseph A Kovacs Journal: PLoS One Date: 2011-01-27 Impact factor: 3.240
Authors: Robert J Blount; Leah G Jarlsberg; Kieran R Daly; William Worodria; J Lucian Davis; Adithya Cattamanchi; Kpandja Djawe; Alfred Andama; Judith Koch; Peter D Walzer; Laurence Huang Journal: PLoS One Date: 2012-12-21 Impact factor: 3.240